Eli Lilly (LLY) partners with British government for a first-of-its-kind real-world study on economic effects of its weight ...

Lilly has been solidly investing in research and development (R&D) throughout 2024. In April, the company announced the ...

Despite this, investors seem to have made up their one-track mind. Eli Lilly’s P/E ratio is more than double that of Novo ...

Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies ...

Unfortunately, many of our elected leaders today undervalue the role of patents to progress the science of drug discovery and ...

Eli Lilly has thrown its weight behind a cause beyond the traditional remit of pharma companies. | Eli Lilly has thrown its ...

Eli Lilly’s senior VP of information and R&D IT, Ramesh Durvasula, said Lilly will use AI and tech to transform the company.

U.S. pharmaceutical giant Eli Lilly is exploring whether obesity drugs could be used to curb joblessness after signing a ...

Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.

In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities ...

There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.

All of this means Lilly investors shouldn't panic. Even in the "worst case," Lilly's weight loss drugs have driven major revenue growth, and this is likely to continue -- whether compounders halt ...